{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ss-31-ibd","title":"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.\n\n## How these fit together\n\nSingle-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.\n\n## What the evidence actually shows\n\nNo human clinical trials test SS-31 specifically in IBD patients (preclinical and mechanistic data only). Preclinical work in DSS-induced colitis mouse models reports improved outcomes including protected intestinal epithelial cells, reduced mucosal inflammation, and lowered oxidative stress markers (site summary from peptidesindex.com, tier: preclinical). Separate animal studies show SS-31 preserves mitochondrial function after inflammatory insults such as lipopolysaccharide exposure, with reduced ROS and maintained ATP in neural and other tissues (Zhao et al., 2019, mouse model, tier: preclinical). Human data exist for other indications: elamipretide received FDA approval in 2025 for Barth syndrome, a primary mitochondrial disorder (multiple reports, tier: human). Phase 2 trials in geographic atrophy and mitochondrial myopathy showed tolerability but mixed functional results (tier: human).\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting antioxidant that concentrates in mitochondria and limits cytochrome c release and permeability transition pore opening (Tung et al., 2025 review, mechanistic). Mitochondrial dysfunction is noted as a feature in IBD models, with altered fission/fusion dynamics in DSS colitis (Mancini et al., 2020, preclinical). Scientists emphasize that benefits in animal colitis models remain exploratory and require human confirmation.\n\n## What people say on Reddit\n\nLimited specific discussion of SS-31 for IBD appears on Reddit. General peptide communities mention mitochondrial peptides for energy or fatigue but rarely link SS-31 directly to colitis or Crohn's experiences (anecdotal tier, sparse).\n\n## What people say on X\n\nPosts on X focus on the 2025 FDA approval for Barth syndrome rather than IBD applications. Occasional mentions of mitochondrial peptides in longevity contexts occur, but no detailed user reports tie SS-31 to IBD symptom changes (anecdotal tier, minimal).\n\n## What we do not know\n\nDirect causation between SS-31 mitochondrial effects and IBD mucosal healing lacks human confirmation. Optimal duration, combination strategies, and long-term tissue outcomes in gut inflammation remain untested in controlled trials. Whether benefits seen in DSS mouse models translate to human Crohn's or colitis histology is unknown. Interaction with standard IBD therapies has no published data.\n\n## Safety and limits\n\nHuman trials report mostly mild injection-site reactions (tier: human). Serious adverse events appear rare in studied populations. SS-31 remains investigational outside approved rare-disease uses. No data establish safety or efficacy for IBD. Research compounds carry regulatory limits on human use beyond approved indications.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.","section":"What's breaking down if you have IBD (Crohn's / colitis)","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Frames the mitochondrial layer targeted by SS-31.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanism linking to repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Only direct IBD-relevant animal data available.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials test SS-31 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Elamipretide received FDA approval in 2025 for Barth syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides context on regulatory status.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7327843/","title":"Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis","quote":"DSS-colitis revealed increased mRNA for molecules associated with mitochondrial fission...","summary":"Links mitochondrial changes to DSS colitis model.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"331cabe4a73207ff483eeedda12907dc3895d5a6ec089485fe3cc9127922cacd"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/","title":"Elamipretide: A Review of Its Structure, Mechanism of Action...","quote":"This mitochondria-targeting tetrapeptide selectively binds cardiolipin...","summary":"Details cardiolipin binding and ROS reduction.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"331cabe4a73207ff483eeedda12907dc3895d5a6ec089485fe3cc9127922cacd","hash":"4f1f7441aab6f37f48e557d8b5099be01ffdaf1599a1068b509bd8b3058a838a"},{"id":"s3","type":"other","url":"https://peptidesindex.com/peptide/ss-31/","title":"SS-31: Revolutionary Mitochondrial Enhancement Peptide","quote":"SS-31 improves outcomes in DSS-induced colitis models by protecting intestinal epithelial cells and reducing mucosal inflammation and oxidative stress.","summary":"Summarizes preclinical colitis findings.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"4f1f7441aab6f37f48e557d8b5099be01ffdaf1599a1068b509bd8b3058a838a","hash":"8307cb12eb4dafb39181e67bbbcedf18bdabd2de07df21dad93fefde0ac52cdc"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction...","quote":"These findings indicate that LPS-induced memory impairment can be attenuated...","summary":"Mouse study on inflammation and mitochondria; no IBD human data.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"8307cb12eb4dafb39181e67bbbcedf18bdabd2de07df21dad93fefde0ac52cdc","hash":"9377b8db07ea3281c534002f21b73495886ea80f54aacdd29aefb23ce7096081"},{"id":"s5","type":"news","url":"https://www.instagram.com/p/DQmV9RaCSEF/?hl=en","title":"FDA Approval Announcement for Elamipretide","quote":"The FDA has officially approved SS-31 (elamipretide)... for the treatment of Barth syndrome","summary":"Reports 2025 approval for rare mitochondrial disease.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"9377b8db07ea3281c534002f21b73495886ea80f54aacdd29aefb23ce7096081","hash":"fafb89ded98f95241992e963a86fab92a2a62e55bcc595b7077cd530156d282e"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:53:01.850Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.\n\n## How these fit together\n\nSingle-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.\n\n## What the evidence actually shows\n\nNo human clinical trials test SS-31 specifically in IBD patients (preclinical and mechanistic data only). Preclinical work in DSS-induced colitis mouse models reports improved outcomes including protected intestinal epithelial cells, reduced mucosal inflammation, and lowered oxidative stress markers (site summary from peptidesindex.com, tier: preclinical). Separate animal studies show SS-31 preserves mitochondrial function after inflammatory insults such as lipopolysaccharide exposure, with reduced ROS and maintained ATP in neural and other tissues (Zhao et al., 2019, mouse model, tier: preclinical). Human data exist for other indications: elamipretide received FDA approval in 2025 for Barth syndrome, a primary mitochondrial disorder (multiple reports, tier: human). Phase 2 trials in geographic atrophy and mitochondrial myopathy showed tolerability but mixed functional results (tier: human).\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting antioxidant that concentrates in mitochondria and limits cytochrome c release and permeability transition pore opening (Tung et al., 2025 review, mechanistic). Mitochondrial dysfunction is noted as a feature in IBD models, with altered fission/fusion dynamics in DSS colitis (Mancini et al., 2020, preclinical). Scientists emphasize that benefits in animal colitis models remain exploratory and require human confirmation.\n\n## What people say on Reddit\n\nLimited specific discussion of SS-31 for IBD appears on Reddit. General peptide communities mention mitochondrial peptides for energy or fatigue but rarely link SS-31 directly to colitis or Crohn's experiences (anecdotal tier, sparse).\n\n## What people say on X\n\nPosts on X focus on the 2025 FDA approval for Barth syndrome rather than IBD applications. Occasional mentions of mitochondrial peptides in longevity contexts occur, but no detailed user reports tie SS-31 to IBD symptom changes (anecdotal tier, minimal).\n\n## What we do not know\n\nDirect causation between SS-31 mitochondrial effects and IBD mucosal healing lacks human confirmation. Optimal duration, combination strategies, and long-term tissue outcomes in gut inflammation remain untested in controlled trials. Whether benefits seen in DSS mouse models translate to human Crohn's or colitis histology is unknown. Interaction with standard IBD therapies has no published data.\n\n## Safety and limits\n\nHuman trials report mostly mild injection-site reactions (tier: human). Serious adverse events appear rare in studied populations. SS-31 remains investigational outside approved rare-disease uses. No data establish safety or efficacy for IBD. Research compounds carry regulatory limits on human use beyond approved indications.","claims":[{"id":"c1","text":"Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.","section":"What's breaking down if you have IBD (Crohn's / colitis)","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Frames the mitochondrial layer targeted by SS-31.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanism linking to repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Only direct IBD-relevant animal data available.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials test SS-31 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Elamipretide received FDA approval in 2025 for Barth syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides context on regulatory status.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7327843/","title":"Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis","quote":"DSS-colitis revealed increased mRNA for molecules associated with mitochondrial fission...","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/","title":"Elamipretide: A Review of Its Structure, Mechanism of Action...","quote":"This mitochondria-targeting tetrapeptide selectively binds cardiolipin...","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"other","url":"https://peptidesindex.com/peptide/ss-31/","title":"SS-31: Revolutionary Mitochondrial Enhancement Peptide","quote":"SS-31 improves outcomes in DSS-induced colitis models by protecting intestinal epithelial cells and reducing mucosal inflammation and oxidative stress.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction...","quote":"These findings indicate that LPS-induced memory impairment can be attenuated...","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"news","url":"https://www.instagram.com/p/DQmV9RaCSEF/?hl=en","title":"FDA Approval Announcement for Elamipretide","quote":"The FDA has officially approved SS-31 (elamipretide)... for the treatment of Barth syndrome","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":30828,"tokens_out":3080,"cost":0.046235,"prev_hash":"genesis","hash":"64a21c89a137e1ce4de51afe094b627fbb9489799675e36f3e2b2ac683009c19"}],"provenance":[{"ts":"2026-06-29T23:53:01.850Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Ibd\nSlug: ss-31-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"ss-31\",\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down if you have IBD (","response":"{\n  \"slug\": \"ss-31-ibd\",\n  \"title\": \"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.\\n\\n## How these fit together\\n\\nSingle-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.\\n\\n## What the evidence actually shows\\n\\nNo human clinical trials test SS-31 specificall","tokens_in":30828,"tokens_out":3080,"cost":0,"prev":"genesis","hash":"ff5749d65447bbfffc793ed48f88c0210c91d576c0e372af71880e620ecba6ba"},{"ts":"2026-07-17T02:42:05.212Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-ibd","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ff5749d65447bbfffc793ed48f88c0210c91d576c0e372af71880e620ecba6ba","hash":"deacefb34aabe75215021139e13a21121a80502d94f7cefeb3c6e95ffa0c4248"}],"energy":{"passes":2,"tokens_in":30828,"tokens_out":3080,"tokens_total":33908,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"deacefb34aabe75215021139e13a21121a80502d94f7cefeb3c6e95ffa0c4248"},"posted_at":"2026-06-29T21:33:23.168Z","created_at":"2026-06-29T21:33:23.168Z","updated_at":"2026-07-17T02:42:05.212Z","machine":{"shape":"article.machine/v1","slug":"ss-31-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-ibd","json":"https://miscsubjects.com/api/articles/ss-31-ibd","bundle":"https://miscsubjects.com/api/articles/ss-31-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-ibd","json":"/api/articles/ss-31-ibd","markdown":"/api/articles/ss-31-ibd/bundle?format=markdown","skill":"/api/articles/ss-31-ibd/skill","topology":"/api/articles/ss-31-ibd/topology","versions":"/api/articles/ss-31-ibd/revisions","invocations":"/api/articles/ss-31-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"2cec7035b8d3b7fd2d056e204684d26ad0884af6d71a99c0cba1ee006a3e86af","object":{"object_type":"article-object","identity":{"id":"article:ss-31-ibd","slug":"ss-31-ibd","title":"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/ss-31-ibd","role":"explain","audience":"human"},"skill":{"route":"/api/articles/ss-31-ibd/skill","role":"direct behavior","audience":"model","content":"---\nname: ss-31-ibd\ndescription: Apply the SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research\n\nThis Skill is the behavioral expression of [the canonical article](/a/ss-31-ibd). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/ss-31-ibd.\n- Read claims and relationships at /api/articles/ss-31-ibd/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have IBD Crohn's / colitis IBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the \n\n## Representations\n\n- Human: /a/ss-31-ibd\n- JSON: /api/articles/ss-31-ibd\n- Relationships: /api/articles/ss-31-ibd/topology\n- History: /api/articles/ss-31-ibd/revisions\n"},"json":{"route":"/api/articles/ss-31-ibd","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/ss-31-ibd/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","ss","31","ibd"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/ss-31-ibd/invocations?status=success","failure_events":"/api/articles/ss-31-ibd/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"ss-31-ibd","title":"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.\n\n## How these fit together\n\nSingle-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.\n\n## What the evidence actually shows\n\nNo human clinical trials test SS-31 specifically in IBD patients (preclinical and mechanistic data only). Preclinical work in DSS-induced colitis mouse models reports improved outcomes including protected intestinal epithelial cells, reduced mucosal inflammation, and lowered oxidative stress markers (site summary from peptidesindex.com, tier: preclinical). Separate animal studies show SS-31 preserves mitochondrial function after inflammatory insults such as lipopolysaccharide exposure, with reduced ROS and maintained ATP in neural and other tissues (Zhao et al., 2019, mouse model, tier: preclinical). Human data exist for other indications: elamipretide received FDA approval in 2025 for Barth syndrome, a primary mitochondrial disorder (multiple reports, tier: human). Phase 2 trials in geographic atrophy and mitochondrial myopathy showed tolerability but mixed functional results (tier: human).\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting antioxidant that concentrates in mitochondria and limits cytochrome c release and permeability transition pore opening (Tung et al., 2025 review, mechanistic). Mitochondrial dysfunction is noted as a feature in IBD models, with altered fission/fusion dynamics in DSS colitis (Mancini et al., 2020, preclinical). Scientists emphasize that benefits in animal colitis models remain exploratory and require human confirmation.\n\n## What people say on Reddit\n\nLimited specific discussion of SS-31 for IBD appears on Reddit. General peptide communities mention mitochondrial peptides for energy or fatigue but rarely link SS-31 directly to colitis or Crohn's experiences (anecdotal tier, sparse).\n\n## What people say on X\n\nPosts on X focus on the 2025 FDA approval for Barth syndrome rather than IBD applications. Occasional mentions of mitochondrial peptides in longevity contexts occur, but no detailed user reports tie SS-31 to IBD symptom changes (anecdotal tier, minimal).\n\n## What we do not know\n\nDirect causation between SS-31 mitochondrial effects and IBD mucosal healing lacks human confirmation. Optimal duration, combination strategies, and long-term tissue outcomes in gut inflammation remain untested in controlled trials. Whether benefits seen in DSS mouse models translate to human Crohn's or colitis histology is unknown. Interaction with standard IBD therapies has no published data.\n\n## Safety and limits\n\nHuman trials report mostly mild injection-site reactions (tier: human). Serious adverse events appear rare in studied populations. SS-31 remains investigational outside approved rare-disease uses. No data establish safety or efficacy for IBD. Research compounds carry regulatory limits on human use beyond approved indications.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.","section":"What's breaking down if you have IBD (Crohn's / colitis)","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Frames the mitochondrial layer targeted by SS-31.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanism linking to repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Only direct IBD-relevant animal data available.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials test SS-31 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Elamipretide received FDA approval in 2025 for Barth syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides context on regulatory status.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7327843/","title":"Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis","quote":"DSS-colitis revealed increased mRNA for molecules associated with mitochondrial fission...","summary":"Links mitochondrial changes to DSS colitis model.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"331cabe4a73207ff483eeedda12907dc3895d5a6ec089485fe3cc9127922cacd"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/","title":"Elamipretide: A Review of Its Structure, Mechanism of Action...","quote":"This mitochondria-targeting tetrapeptide selectively binds cardiolipin...","summary":"Details cardiolipin binding and ROS reduction.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"331cabe4a73207ff483eeedda12907dc3895d5a6ec089485fe3cc9127922cacd","hash":"4f1f7441aab6f37f48e557d8b5099be01ffdaf1599a1068b509bd8b3058a838a"},{"id":"s3","type":"other","url":"https://peptidesindex.com/peptide/ss-31/","title":"SS-31: Revolutionary Mitochondrial Enhancement Peptide","quote":"SS-31 improves outcomes in DSS-induced colitis models by protecting intestinal epithelial cells and reducing mucosal inflammation and oxidative stress.","summary":"Summarizes preclinical colitis findings.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"4f1f7441aab6f37f48e557d8b5099be01ffdaf1599a1068b509bd8b3058a838a","hash":"8307cb12eb4dafb39181e67bbbcedf18bdabd2de07df21dad93fefde0ac52cdc"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction...","quote":"These findings indicate that LPS-induced memory impairment can be attenuated...","summary":"Mouse study on inflammation and mitochondria; no IBD human data.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"8307cb12eb4dafb39181e67bbbcedf18bdabd2de07df21dad93fefde0ac52cdc","hash":"9377b8db07ea3281c534002f21b73495886ea80f54aacdd29aefb23ce7096081"},{"id":"s5","type":"news","url":"https://www.instagram.com/p/DQmV9RaCSEF/?hl=en","title":"FDA Approval Announcement for Elamipretide","quote":"The FDA has officially approved SS-31 (elamipretide)... for the treatment of Barth syndrome","summary":"Reports 2025 approval for rare mitochondrial disease.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:53:00.657Z","link_status":"ok","quote_status":"unverified","prev":"9377b8db07ea3281c534002f21b73495886ea80f54aacdd29aefb23ce7096081","hash":"fafb89ded98f95241992e963a86fab92a2a62e55bcc595b7077cd530156d282e"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:53:01.850Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.\n\n## How these fit together\n\nSingle-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.\n\n## What the evidence actually shows\n\nNo human clinical trials test SS-31 specifically in IBD patients (preclinical and mechanistic data only). Preclinical work in DSS-induced colitis mouse models reports improved outcomes including protected intestinal epithelial cells, reduced mucosal inflammation, and lowered oxidative stress markers (site summary from peptidesindex.com, tier: preclinical). Separate animal studies show SS-31 preserves mitochondrial function after inflammatory insults such as lipopolysaccharide exposure, with reduced ROS and maintained ATP in neural and other tissues (Zhao et al., 2019, mouse model, tier: preclinical). Human data exist for other indications: elamipretide received FDA approval in 2025 for Barth syndrome, a primary mitochondrial disorder (multiple reports, tier: human). Phase 2 trials in geographic atrophy and mitochondrial myopathy showed tolerability but mixed functional results (tier: human).\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting antioxidant that concentrates in mitochondria and limits cytochrome c release and permeability transition pore opening (Tung et al., 2025 review, mechanistic). Mitochondrial dysfunction is noted as a feature in IBD models, with altered fission/fusion dynamics in DSS colitis (Mancini et al., 2020, preclinical). Scientists emphasize that benefits in animal colitis models remain exploratory and require human confirmation.\n\n## What people say on Reddit\n\nLimited specific discussion of SS-31 for IBD appears on Reddit. General peptide communities mention mitochondrial peptides for energy or fatigue but rarely link SS-31 directly to colitis or Crohn's experiences (anecdotal tier, sparse).\n\n## What people say on X\n\nPosts on X focus on the 2025 FDA approval for Barth syndrome rather than IBD applications. Occasional mentions of mitochondrial peptides in longevity contexts occur, but no detailed user reports tie SS-31 to IBD symptom changes (anecdotal tier, minimal).\n\n## What we do not know\n\nDirect causation between SS-31 mitochondrial effects and IBD mucosal healing lacks human confirmation. Optimal duration, combination strategies, and long-term tissue outcomes in gut inflammation remain untested in controlled trials. Whether benefits seen in DSS mouse models translate to human Crohn's or colitis histology is unknown. Interaction with standard IBD therapies has no published data.\n\n## Safety and limits\n\nHuman trials report mostly mild injection-site reactions (tier: human). Serious adverse events appear rare in studied populations. SS-31 remains investigational outside approved rare-disease uses. No data establish safety or efficacy for IBD. Research compounds carry regulatory limits on human use beyond approved indications.","claims":[{"id":"c1","text":"Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.","section":"What's breaking down if you have IBD (Crohn's / colitis)","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Frames the mitochondrial layer targeted by SS-31.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanism linking to repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Only direct IBD-relevant animal data available.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials test SS-31 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Elamipretide received FDA approval in 2025 for Barth syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides context on regulatory status.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:53:01.221Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7327843/","title":"Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis","quote":"DSS-colitis revealed increased mRNA for molecules associated with mitochondrial fission...","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/","title":"Elamipretide: A Review of Its Structure, Mechanism of Action...","quote":"This mitochondria-targeting tetrapeptide selectively binds cardiolipin...","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"other","url":"https://peptidesindex.com/peptide/ss-31/","title":"SS-31: Revolutionary Mitochondrial Enhancement Peptide","quote":"SS-31 improves outcomes in DSS-induced colitis models by protecting intestinal epithelial cells and reducing mucosal inflammation and oxidative stress.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction...","quote":"These findings indicate that LPS-induced memory impairment can be attenuated...","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"news","url":"https://www.instagram.com/p/DQmV9RaCSEF/?hl=en","title":"FDA Approval Announcement for Elamipretide","quote":"The FDA has officially approved SS-31 (elamipretide)... for the treatment of Barth syndrome","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":30828,"tokens_out":3080,"cost":0.046235,"prev_hash":"genesis","hash":"64a21c89a137e1ce4de51afe094b627fbb9489799675e36f3e2b2ac683009c19"}],"provenance":[{"ts":"2026-06-29T23:53:01.850Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Ibd\nSlug: ss-31-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"ss-31\",\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down if you have IBD (","response":"{\n  \"slug\": \"ss-31-ibd\",\n  \"title\": \"SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.\\n\\n## How these fit together\\n\\nSingle-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.\\n\\n## What the evidence actually shows\\n\\nNo human clinical trials test SS-31 specificall","tokens_in":30828,"tokens_out":3080,"cost":0,"prev":"genesis","hash":"ff5749d65447bbfffc793ed48f88c0210c91d576c0e372af71880e620ecba6ba"},{"ts":"2026-07-17T02:42:05.212Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-ibd","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ff5749d65447bbfffc793ed48f88c0210c91d576c0e372af71880e620ecba6ba","hash":"deacefb34aabe75215021139e13a21121a80502d94f7cefeb3c6e95ffa0c4248"}],"energy":{"passes":2,"tokens_in":30828,"tokens_out":3080,"tokens_total":33908,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"deacefb34aabe75215021139e13a21121a80502d94f7cefeb3c6e95ffa0c4248"},"posted_at":"2026-06-29T21:33:23.168Z","created_at":"2026-06-29T21:33:23.168Z","updated_at":"2026-07-17T02:42:05.212Z","machine":{"shape":"article.machine/v1","slug":"ss-31-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-ibd","json":"https://miscsubjects.com/api/articles/ss-31-ibd","bundle":"https://miscsubjects.com/api/articles/ss-31-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-ibd","json":"/api/articles/ss-31-ibd","markdown":"/api/articles/ss-31-ibd/bundle?format=markdown","skill":"/api/articles/ss-31-ibd/skill","topology":"/api/articles/ss-31-ibd/topology","versions":"/api/articles/ss-31-ibd/revisions","invocations":"/api/articles/ss-31-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"2cec7035b8d3b7fd2d056e204684d26ad0884af6d71a99c0cba1ee006a3e86af"}}}